Shares of Clearmind Medicine Inc. (NASDAQ:CMND) fell roughly 33% on Tuesday after the clinical-stage biotechnology company said it will implement a 1-for-10 reverse share split, effective May 21, 2026.
The company said the reverse split is part of an effort to regain compliance with the Nasdaq Minimum Bid Price Rule. Clearmind's board of directors approved the action on March 18, 2026.
Under the approved plan, the number of issued and outstanding common shares will be reduced from 10,190,337 to about 1,019,033 following the reverse split. Clearmind emphasized that its authorized share capital will remain unchanged and effectively unlimited.
The company also stated that no fractional shares will be issued as a result of the reverse split. Any fractional holdings that would otherwise result will be rounded up to the nearest whole share. In addition, Clearmind will make proportionate adjustments to the per-share exercise price and the number of shares issuable upon exercise of all outstanding options or warrants.
Clearmind Medicine is focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics.
Context and mechanics
The reverse split announced by the board reduces the company’s share count by a factor of ten and will change the arithmetic for shares, options and warrants. The company has stated the mechanics for fractional shares and for adjustments to exercisable securities, but has not changed its authorized capital ceiling.
Market reaction
Following the announcement, the market reacted with a sharp decline in the stock price, reflecting investors’ immediate response to the company’s move to amend its share structure. The 33% intraday drop occurred on the day the reverse-split plan was disclosed.
Company focus
Clearmind operates in the clinical-stage biotech sector, with a program concentrating on non-hallucinogenic neuroplastogen-based therapies. The announced corporate action relates to the company’s listing status rather than to a change in its stated research and development focus.
Summary
Clearmind Medicine will implement a 1-for-10 reverse share split on May 21, 2026, after board approval on March 18, 2026. The move is intended to restore compliance with Nasdaq listing rules, will reduce outstanding shares from 10,190,337 to approximately 1,019,033, leave authorized capital unlimited, round fractional shares up to whole shares, and adjust outstanding options and warrants proportionately. The stock fell about 33% on the announcement.